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Letters to the
Editor
Chronic ischemic mitral
regurgitation: Types and subtypes
To the Editor:
We have read with great interest the three
contributions concerning ischemic mitral
regurgitation (IMR) recently published in
the Journal.1-3 All authors give the im-
pression that a definition of subgroups of
patients is urgently needed to permit uni-
form reporting, compare surgical results,
and tailor the optimal surgical option for
each patient. However, different classifi-
cation schemes are suggested in each ar-
ticle. According to Steven Bolling’s
well-known statement that “IMR is a
ventricular disease, not a valvular dis-
ease,” we also believe that a more de-
tailed analysis of the different aspects of
postinfarction ventricular pathophysiol-
ogy would be advisable. The proposed
classification of chronic IMR is described
in Table 1.
It is often difficult to give a clear cutoff
between “regional” and “global” dysfunc-
tion (types 1 and 2), but the distinction
appears useful owing to the poorer natural
history and less satisfactory surgical out-
come in the presence of advanced ventric-
ular remodeling. In this classification, the
term “ventricular-papillary dysfunction,”
introduced by Grossi and coworkers,2 is
used in a broader sense. It refers not only to
papillary muscle fibrosis, but also to papil-
lary muscle displacement and tethering of
mitral cusps (subtype A) and to annular
dilation resulting from postinfarction ven-
tricular remodeling (subtype B). In fact,
both mechanisms frequently coexist (sub-
type C): annular dilation is very common in
global ventricular-papillary dysfunction,
whereas regional dysfunction generally
correlates with papillary muscle (usually
posteromedial) atrophy or elongation. In
this setting, varying degrees of each patho-
physiologic mechanism should probably
best be addressed by specific surgical re-
pair.
Unlike others,2 we did not include the
term “isolated annular dilation” in the
classification because, in our opinion, di-
lation of the mitral anulus appears corre-
lated to left ventricular dysfunction and
therefore does not represent the primary
cause of regurgitation. Likewise, we only
considered “functional regurgitation”
subtypes and did not include insuffi-
ciency caused by structural damage (rup-
tured papillary muscle or chordal disin-
sertion).
This subdivision does not introduce
new concepts; rather, it tries to classify all
known pathophysiologic mechanisms of
chronic functional IMR with the purpose to
select patients for specific surgical correc-
tion and, most important, compare results
of operations in similar subgroups of pa-
tients.
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TABLE 1. Chronic functional ischemic mitral regurgitation varieties
Ventricular-papillary dysfunction
Regional (type 1) Global (type 2)
Papillary muscle(s) atrophy, elongation, or
displacement (subtype A)
1A 2A
Annular dilation (subtype B) 1B 2B
A and B (subtype C) 1C 2C
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Reply to the Editor:
Fundaro` and colleagues address the histor-
ically difficult task of creating a universally
accepted classification system for ischemic
mitral regurgitation (IMR). As they note,
multiple systems are used for the descrip-
tion of IMR. In fact, the three articles that
Fundaro` and coworkers cite,1-3 all of which
appeared in the same issue of the Journal,
contain slightly different categorizations
for IMR. The most important point, how-
ever, is that these three classification sys-
tems are actually quite similar to one an-
other. All are based on the mechanism(s) of
IMR.
Recent observations have furthered our
understanding of the pathophysiology of
IMR. In some instances, the mechanisms of
IMR are quite complicated; therefore,
some precision may be sacrificed as each
patient is placed in a single group that
specifies the predominant mechanism.
Nevertheless, such categorization will fa-
cilitate more meaningful communication of
the nature of IMR.
The authors of the three articles agree
that IMR may be caused by papillary mus-
cle disease or by changes in ventricular
and/or annular geometry, the latter result-
ing in functional IMR. Occasionally, more
than one of these mechanisms is operative.
Miller’s classification system1 is particu-
larly useful. He suggests that the primary
mechanism of IMR generally falls into one
of the following categories:
1. Papillary muscle rupture
2. Papillary muscle infarction and elon-
gation without rupture
3. Functional IMR from
a. Annular dilatation
b. Leaflet tethering
c. Annular dilatation and leaflet teth-
ering
By means of echocardiography, the major-
ity of patients with IMR can be placed into
one of these groups.
Fundaro` and colleagues offer a classifi-
cation system that is similar to the others
mentioned here. However, their distinction
between regional and global left ventricular
dysfunction does not speak directly to the
mechanism of IMR. Rather, it introduc-
esanother type of classification system. In
addition, subtype A (papillary muscle atro-
phy, elongation, or displacement) contains
disparate entities with different mecha-
nisms of IMR.
Classification systems have a long his-
tory of value in cardiac surgery and medi-
cine in general. They are designed to reflect
understanding of the nature of diseases (eg,
Miller’s classification of IMR), to facilitate
guidelines and indications for treatment
(eg, American Heart Association guide-
lines), to allow complex observations to be
communicated effectively (eg, nomencla-
ture for heart disease), and to reflect differ-
ences in prognosis (eg, cancer staging).
Fundaro`’s classification attempts to reflect
three different purposes of classification
systems simultaneously: mechanism, indi-
cations for operation, and prognosis. This
may be too ambitious, given the complex
nature of IMR.
We, Miller, and Grossi and colleagues
propose classification systems that address
clarity in understanding the mechanisms of
IMR. Choice of operation based on optimi-
zation of prognosis is a far more complex
and multifactorial issue that, at present, is
not clearly amenable to simple classifica-
tion.
Given our improved understanding of
the mechanisms of IMR, it is time that we
adopted a common classification system.
We recommend following Miller’s lead;
his mechanism-based description of IMR
permits clear categorization of patients.
A. Marc Gillinov, MD
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What are the best temperature, flow,
and hematocrit levels for pediatric
cardiopulmonary bypass?
To the Editor:
I read with great pleasure the letter by
Durandy, Hulin, and Lecompte1 on normo-
thermic cardiopulmonary bypass in pediat-
ric surgery, as well as the reply by Jonas,
Newburger, and Bellinger.2
I spent 1 year with Durandy and
Lecompte in Paris in 1995, at the beginning
of their experience with normothermic car-
diopulmonary bypass, and witnessed the
extremely smooth and “physiologic” post-
operative course of more than 300 consec-
utive children with congenital heart de-
fects. Most of them had very complicated
anatomy and intracardiac repair, and al-
most all of them were extubated very early,
without the need for inotropic support. I
repeatedly suggested that Durandy and
Lecompte report their extraordinary expe-
rience. Their reason for refusing to report
their data at that time was the need for
more substantial background.
I then decided to follow their methods
of cardiopulmonary bypass, and the initial
experience has been already reported.3,4
Therefore, I viewed the publication of their
letter with a great sense of relief, because
the feasibility and the advantages of nor-
mothermic cardiopulmonary bypass have
been now supported by their experience
with 1600 congenital cases.
To further support the message given in
the letter, I feel obliged to extend the in-
formation provided by Durandy, Hulin, and
Lecompte. In their letter they discussed
only the problem of temperature, although
there are at least other three factors used in
their practice of cardiopulmonary bypass
that contributed to their good results: flow,
hematocrit, and leukocyte depletion.
1. Flow. The flow generally used for
cardiopulmonary bypass is 2.0 to 2.4
L  m2  min1 or 100 to 120 mL 
kg1 min1. Even if this flow rate is
accepted as the gold standard for ad-
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